Navepegritide
As of the edition of 20 October 2026, Navepegritide is a protein: marketed, first approved in 2026 (US); acts on NPR2; US protection ends in 2037.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Protein
- Brand name
- Yuviwel
- First approved
- 27 February 2026 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Ascendis Pharma A/S
- Registered trials
- 6, 0 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Hormones
US protection
US protection ends in 2037.
The last listed US drug-substance patent ends in 2037. The application that gives this date is held by Ascendis Pharma A/S.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product27 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 27 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Navepegritide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NPR2 | Atrial natriuretic peptide receptor 2 | P20594 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 2 | 2 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ascendis Pharma A/S | Originator and Lead sponsor of trials | 2020 to now |